OverviewSuggest Edit

Lipocine is a specialty pharmaceutical company developing pharmaceutical products using its oral drug delivery technology in the areas of men's and women's health. The Company offers a portfolio of proprietary product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is LPCN 1021, an oral testosterone replacement therapy.

TypePublic
Founded1997
HQSalt Lake City, US
Websitelipocine.com

Latest Updates

Employees (est.) (Dec 2018)10(-28%)
Job Openings3
Revenue (FY, 2018)$428 K
Share Price (Jun 2019)$1.5

Key People/Management at Lipocine

Mahesh V. Patel

Mahesh V. Patel

Chairman, President and Chief Executive Officer
Morgan Brown

Morgan Brown

Executive Vice President and Chief Financial Officer
Greg Bass

Greg Bass

Executive Vice President and Chief Commercial Officer
Jyrki Mattila

Jyrki Mattila

Executive Vice President and Chief Business Officer
Anthony DelConte

Anthony DelConte

Chief Medical Director
Show more

Lipocine Office Locations

Lipocine has offices in Salt Lake City and Trenton
Salt Lake City, US (HQ)
675 Arapeen Dr #202
Trenton, US
3150 Brunswick Pike #130
Show all (2)

Lipocine Financials and Metrics

Lipocine Revenue

Lipocine's revenue was reported to be $428.03 k in FY, 2018
USD

Revenue (FY, 2018)

428.0k

Net income (FY, 2018)

(11.7m)

EBIT (FY, 2018)

(11.3m)

Market capitalization (10-Jun-2019)

32.1m

Closing stock price (10-Jun-2019)

1.5

Cash (31-Dec-2018)

8.1m
Lipocine's current market capitalization is $32.1 m.
Annual
USDFY, 2013Y, 2013FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

428.0k

General and administrative expense

3.6m5.8m10.4m10.2m5.3m

R&D expense

5.1m12.6m8.1m11.0m6.5m

Operating expense total

10.7m18.4m19.2m21.2m11.8m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Revenue

428.0k428.0k

General and administrative expense

1.2m1.9m1.0m871.8k1.1m1.1m1.7m4.4m3.2m1.4m1.8m2.0m1.7m1.7m

R&D expense

1.6m3.4m6.0m3.2m1.9m3.2m4.7m2.7m2.6m1.5m3.1m4.1m1.4m1.5m

Operating expense total

2.8m5.3m7.0m4.1m3.0m4.3m6.4m7.1m5.8m3.3m4.9m6.1m4.8m3.1m3.2m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

45.3m27.7m20.0m5.6m3.2m8.1m

Accounts Receivable

Inventories

Current Assets

46.0m27.9m44.9m27.2m25.2m20.8m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

36.8m41.8m34.2m31.7m24.8m38.3m23.9m14.1m12.4m4.7m6.9m16.6m9.3m8.6m1.6m

Current Assets

37.1m42.0m35.4m32.0m25.0m44.1m42.3m38.6m33.2m29.4m27.1m27.9m26.1m31.6m25.3m

Total Assets

37.2m42.1m35.5m32.0m25.1m53.8m48.4m38.8m33.3m29.6m27.2m28.0m26.3m31.7m25.3m

Accounts Payable

1.5m773.0k641.8k399.1k379.5k398.8k456.8k1.1m989.0k865.0k853.5k1.1m803.8k388.4k406.5k
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(10.6m)(20.4m)(18.2m)(19.0m)(21.0m)(11.7m)

Depreciation and Amortization

21.8k14.6k26.7k32.0k28.4k18.6k

Inventories

Accounts Payable

668.8k(449.6k)200.8k(261.2k)352.2k73.2k
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Net Income

(6.2m)(5.3m)(12.2m)(16.3m)(3.0m)(7.2m)(13.6m)(7.0m)(12.8m)(3.2m)(4.9m)(11.0m)(4.7m)(2.7m)(6.0m)

Depreciation and Amortization

15.7k3.0k6.1k9.4k8.7k19.6k6.7k15.5k7.1k14.2k5.3k9.7k

Accounts Payable

1.1m(254.0k)(385.2k)(627.9k)379.5k30.1k150.6k570.1k482.0k865.0k607.6k867.9k803.8k(209.7k)(191.5k)

Purchases of PP&E

(1.2k)(1.9k)(1.9k)(21.3k)(14.8k)(28.7k)(39.2k)(59.6k)
USDY, 2018

Revenue/Employee

42.8k

Financial Leverage

2.2 x
Show all financial metrics

Lipocine Online and Social Media Presence

Embed Graph

Lipocine News and Updates

Lipocine Seeks Injunction Against the Marketing of Clarus Therapeutics' JATENZO® for Testosterone Replacement Therapy

SALT LAKE CITY, April 3, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it has filed suit against Clarus Therapeutics, Inc. ("Clarus") in the United States District Court...

Lipocine Announces Successful Ex Vivo Conversion Assessment of TLANDO™

SALT LAKE CITY, Dec. 31, 2018 /PRNewswire/ -- Lipocine, Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced completion of a definitive phlebotomy study ("Phlebotomy Study") to assess the extent, if any, of clinically meaningful ex vivo conversion of testosterone...

Lipocine Announces LPCN 1144 Clinical Trial Results Selected for Presentation at 2019 NASH-TAG Conference

SALT LAKE CITY, Dec. 21, 2018 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that it has been selected to present LPCN 1144 results as part of the 2019 NASH-TAG Conference. The presentation will highlight data from multiple clinical...

Lipocine Announces Financial and Operational Results for the Three and Nine Months Ended September 30, 2018

SALT LAKE CITY, Nov. 7, 2018 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced financial results for the three and nine months ended September 30, 2018. Third Quarter and Recent Corporate Highlights Completed enrollment of 138 subjects in...

Lipocine to Present at the Ladenburg Thalmann 2018 Healthcare Conference

SALT LAKE CITY, Sept. 25, 2018 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will provide a corporate overview at the Ladenburg Thalmann 2018 Healthcare Conference, being held October...

Lipocine Announces Financial and Operational Results for the Second Quarter and Six Months Ended June 30, 2018

SALT LAKE CITY, Aug. 7, 2018 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced financial results for the three and six months ended June 30, 2018. Second Quarter and Recent Corporate Highlights Received a Complete Response Letter ("CRL")...

Lipocine Frequently Asked Questions

  • When was Lipocine founded?

    Lipocine was founded in 1997.

  • Who are Lipocine key executives?

    Lipocine's key executives are Mahesh V. Patel, Morgan Brown and Greg Bass.

  • How many employees does Lipocine have?

    Lipocine has 10 employees.

  • What is Lipocine revenue?

    Latest Lipocine annual revenue is $428 k.

  • What is Lipocine revenue per employee?

    Latest Lipocine revenue per employee is $42.8 k.

  • Who are Lipocine competitors?

    Competitors of Lipocine include Kither Biotech, CANbridge Life Sciences and Cognition Therapeutics.

  • Where is Lipocine headquarters?

    Lipocine headquarters is located at 675 Arapeen Dr #202, Salt Lake City.

  • Where are Lipocine offices?

    Lipocine has offices in Salt Lake City and Trenton.

  • How many offices does Lipocine have?

    Lipocine has 2 offices.